

ANTIBIOTIC RESISTANCE AND INTEGRON GENE CASSETTES IN ACINETOBACTER BAUMANNII ISOLATES PRODUCED IN LOWER RESPIRATORY TRACT SAMPLES TAKEN FROM THE INTENSIVE CARE UNIT

Yoğun Bakım Ünitesinden Alınan Alt Solunum Yolu Örneklerinde Üretilen Acinetobacter baumannii İzolatlarında Antibiyotik Direnci ve Integron Gen Kasetleri

Uğur KOSTAKOĞLU¹, Ayse ERTÜRK², İknur Esen YILDIZ³, Songül ÖZYURT⁴,
Ayşegül ÇOPUR ÇİÇEK⁵, Mevlüt KARATAŞ⁶, Emine SÖNMEZ⁷

^{1,2,3}Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi, Enfeksiyon Hast. ve Klinik Mikrobiyoloji A.D., RİZE, TÜRKİYE

^{4,6}Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları A.D., RİZE, TÜRKİYE

⁵Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji A.D., RİZE, TÜRKİYE

⁷Beykent Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji A.D., İSTANBUL, TÜRKİYE

ABSTRACT

ÖZ

Objective: The spread of antibiotic resistance genes among bacteria causes serious problems in the treatment of infectious diseases. Recently, it has been shown that these resistance genes are also found in integrons. This study investigated the class 1, 2 integrons and the antibiotic-resistant genes in the infection agent *Acinetobacter baumannii* produced in respiratory tract samples.

Material and Methods: The study involved 86 *A. baumannii* strains isolated from lower respiratory tract samples collected between March 2014 and March 2015 in the Intensive Care Units. Identification and antibiograms of the isolates were made using conventional methods and Vitek 2 Compact systems. The presence of integrons in strains was investigated by polymerase chain reaction method using specific primer pairs for class 1 and class 2 integrase regions. All samples in which integron amplification was carried out were subjected to DNA sequence analysis both by cloning and as a PCR product. The resistance genes were screened by polymerase chain reaction.

Results: Isolates were obtained from specimens including tracheal aspirates (33.7%), bronchoalveolar lavage (29.1%), sputum (22.1%), bronchial washing fluid/bronchial brushing (4.7%), transbronchial biopsy (4.7%), pleural fluid (3.4%) and lung aspirates/abscess (2.3%). While resistance to imipenem, meropenem, ampicillin-sulbactam, ceftazidime, and piperacillin-tazobactam was determined in all isolates, resistance rates to ciprofloxacin, levofloxacin, gentamicin, amikacin and tigecycline were 97.7%, 93.0%, 60.5%, 53.5% and 9.3%, respectively. Colistin was the only antibiotic to which all strains were susceptible. The positivity rates of integrase I and II genes were 45.4% and 9.3%, respectively. Class 1 and 2 integron positivity rates in all isolates were 31.4% and 8.1%, respectively. *bla*TEM, *bla*SHV, *bla*CTX-M1, *bla*CTX-M2, *bla*OXA23, *bla*OXA40, *bla*OXA58 were 70.9%, 2.3%, 4.7%, 7.0%, 95.3%, 5.8% and 3.5%, respectively.

Conclusion: Increasing association of multi drug resistant strains and integron resistant genes in *A. baumannii* infections will lead to the failure of antibiotic treatment strategies.

Amaç: Antibiyotik direnç genlerinin bakteriler arasındaki yayılımı, enfeksiyon hastalıklarının tedavisinde ciddi sorunlara yol açmaktadır. Son zamanlarda bu direnç genlerin integronlarda da bulunduğu gösterilmiştir. Bu çalışmada alt solunum yollarından alınan kültürlerde üretilen enfeksiyon etkeni olan *Acinetobacter baumannii* suşlarında sınıf 1, sınıf 2 integron varlığı ve antibiyotik direnç genleri araştırıldı.

Gereç ve Yöntemler: Çalışmaya, Mart 2014- Mart 2015 tarihleri arasında alt solunum yolu örneklerinden izole edilen toplam 86 *A. baumannii* suşu dahil edildi. İzolatların tanımlanması ve antibiyogramları konvansiyonel metodlar ve Vitek 2 Compact sistemleriyle yapıldı. Suşlarda integron varlığı, sınıf 1 (*intI1*) ve sınıf 2 (*intI2*) integrase bölgeleri için özgül primer çiftleri kullanılarak PCR yöntemiyle araştırıldı. Integron amplifikasyonunun gerçekleştirildiği tüm örnekler hem klonlanarak hem de PCR ürünü olarak DNA dizi analizine tabi tutuldu. Direnç genleri polimeraz zincir reaksiyonu ile tarandı.

Bulgular: İzolatlar trakeal aspiratlar (%33.7), bronkoalveoler lavaj (%29.1), balgam (%22.1), bronşiyal yıkama sıvısı / bronşiyal fırçalama (%4.7), transbronşiyal biyopsi (%4.7), plevral sıvı (%3.4) ve akciğer aspirasyonları / apse (%2.3) örneklerinden elde edildi. Tüm izolatlarda imipenem, meropenem, seftazidim, piperasillin-tazobaktam, ampisilin-sulbaktam karşı direnç saptanırken, siprofloksasin, levofloksasin, gentamisin, amikasin ve tigesikline karşı direnç sırasıyla %97.7, %93.0, %60.5, %53.5 ve %9.3 olarak tespit edildi. Kolistin, tüm suşlara karşı tek etkin antibiyotikti. Integraz I ve II gen pozitiflik oranı sırasıyla %45.4 ve %9.3 iken, sınıf 1 ve 2 integron pozitiflik oranı tüm izolatlarda sırasıyla %31.4 ve %8.1 olarak bulundu. *bla*TEM, *bla*SHV, *bla*CTX-M1, *bla*CTX-M2, *bla*OXA23, *bla*OXA40, *bla*OXA58 sırasıyla %70.9, %2.3, %4.7, %7.0, %95.3, %5.8 ve %3.5 bulundu.

Sonuç: *A. baumannii* enfeksiyonlarında çoklu ilaç direnci olan suşların ve integron direnç genlerinin birlikte artışı, antibiyotik tedavi stratejilerinin başarısızlığına yol açacaktır.

Keywords: *Acinetobacter baumannii*; Lower respiratory tract specimens; Integron; Antibiotic-resistant genes

Anahtar Kelimeler: *Acinetobacter baumannii*; Alt solunum yolu örnekleri; Integron; Antibiyotik direnç genleri



Correspondence / Yazışma Adresi:

Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi, Enfeksiyon Hast.ve Klinik Mikrobiyoloji A.D., Rize Türkiye
Phone / Tel: +90 505 2536325

Received / Geliş Tarihi: 03.11.2020

ORCID NO: ¹0000-0002-4589-0962, ²0000-0002-2222-5580

⁵0000-0002-3673-9670, ⁶0000-0003-2524-9964

Dr. Uğur KOSTAKOĞLU

Enfeksiyon Hast.ve Klinik Mikrobiyoloji A.D., Rize Türkiye

E-mail / E-posta: ugurkostakoglu@yahoo.com

Accepted / Kabul Tarihi: 21.12.2020

³0000-0003-2987-0483, ⁴0000-0003-2987-0483

⁷0000-0003-4418-5599

INTRODUCTION

Lower respiratory tract infections are a major cause of morbidity and mortality in hospitalized patients. *Acinetobacter baumannii* (*A. baumannii*) causes serious healthcare-related infections and its incidence has increased with many strains that have become resistant to many antibiotic classes over the past decades (1).

Mutations and transfer of resistance determinants in multi drug resistant (MDR) isolates via plasmids, transposons and integrons have caused an increase in *A. baumannii* infections. This has now become a major problem worldwide (2,3).

In recent years, the presence of mobile DNA elements has been implicated in the transfer of bacteria-resistant genes from bacteria, and these may be integrated in the bacteria genome with a 'site-specific' recombination mechanism causing resistance. These mobile DNA elements are known as integrons and are found in plasmids and transposons. Integrons have been implicated in the epidemiological spread of resistance to antibiotics between isolates (4). The increasing prevalence of β -lactamase enzymes has reduced susceptibility to carbapenems. Class D β -lactamases (OXA-type) and Ambler class B metallo- β -lactamase provide the most significant contributions to carbapenem resistance. Another resistance mechanism is clavulanic-acid-inhibited extended-spectrum β -lactamases (ESBLs), consisting of PER-1, PER-2, VEB-1, MBLs, VIM-1/4, VIM-2 and IMP-1,2,4,5,6 type genes. If MDR *A. baumannii* infections are not brought under control, they may cause nosocomial epidemics, and these may spread among hospitals, between cities and even across countries. Investigation of the resistance mechanisms of MDR *A. baumannii* will therefore represent an important step in combating such infections (5,6).

The purpose of this study was to investigate class 1 and 2 integrons of the infection agent in *A. baumannii*

strains isolated from lower respiratory tract clinical samples and to characterize the antibiotic-resistance genes carried by these.

MATERIALS AND METHODS

Bacterial Isolates and Antimicrobial Sensitivity Tests

The study investigated 86 non-duplicate samples taken from patients in Recep Tayyip Erdoğan Training and Research Hospital (RTETRH) intensive care units (ICU) between March 2014 and March 2015. Over the one-year study period, 1698 patients were admitted to ICU of 36,840 hospitalized patients in the RTETRH. Respectively there are 9, 8, 6, 16 beds in the surgery intensive care unit, the medical intensive care unit, the cardiovascular surgery intensive care unit, the coronary care unit. All intensive care units have ventilator equipment.

Samples were sent to the microbiology laboratory and were confirmed as producing the infection agent. The clinical isolates were identified using conventional methods and the Vitek 2 Compact system (BioMerieux, France). Isolates were evaluated for sensitivity to amikacin, gentamicin, ciprofloxacin, levofloxacin, ceftazidime, piperacillin-tazobactam, trimethoprim/sulfamethoxazole, meropenem, imipenem, sulbactam/ampicillin, colistin, and tigecycline. *Pseudomonas aeruginosa* ATCC 27853 was used as the quality control strain. The antimicrobial sensitivity experiments were evaluated based on Clinical and Laboratory Standards Institute criteria (7). For tigecycline, the E test was applied and the MIC (Minimum Inhibitor Concentration) results determined were evaluated based on the criteria recommended by the Food and Drug Administration for Enterobacteriaceae (≤ 2 mg/L sensitive, 4 mg/L moderate sensitivity and ≥ 8 mg/L resistant) (8).

DNA Extraction and PCR Assays for Integrons

Genomic DNA was extracted from bacterial suspensions incubated overnight in Luria Broth with

oscillations at a temperature of 37° C. These suspensions were then subjected to centrifugation at 13,000 rpm for 5 min. Pellets were subsequently placed into 500 µL distilled water and boiled for 10 min. In the final stage, debris was subjected to centrifugation at 13,000 rpm for 5 min. Five microliters were extracted from each supernatant for use as a template for PCR. Resistance genes and integron-specific PCR assays were applied according to the protocol previously described by Cicek et al (9).

The genes and primers used in PCR to determine the resistance of the genes are shown in Table 1. All PCR findings were evaluated on 1% agarose containing 0.5 mg/L ethidium bromide prior to visualization under ultraviolet light. A 100 bp DNA marker in the gel controls was used as a molecular marker (100 bp DNA Ladder, New England Biolabs, UK).

Base Sequence Analysis: Base sequence analysis was applied to all the samples by cloning after integron amplification (MacroGen, Holland). Competent cells of *Escherichia coli* JM101 root were prepared using the calcium chloride method. In order to determine the base sequence, ligation was achieved to the pGEM-T easy vector (Promega, USA) of the PCR products, following the manufacturer's protocol. The ligation products were transformed to the previously prepared *E. coli* JM101 competent cells. Cells containing plasmids carrying the PCR product were planted by smearing on petri dishes with LB agar with ampicillin (50µg/ml) containing 1mM IPTG and X-Gal. Cells were separated by examination of the formation of a blue-white color.

The plasmid was isolated by selecting a white colony from each petri dish (Wizard Plus SV Minipreps DNA Purification System, Promega, USA) and was maintained in agarose gel by cutting with EcoRI

restriction endonuclease enzyme. PCR product was used as a control and for nucleotide sequence analysis. Plasmids giving the same fragment as the PCR product were regarded as positive and were sent to MacroGen Inc. (Amsterdam, Holland). Base sequence analysis of the DNA sequence in the clone plasmids was performed using T7 promoter and SP6 primers on pGEM-T. For Bioinformatic comparisons, BLAST analyses were applied on the NCBI and Expasy (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) websites. Amino acid sequences were used for comparisons.

The study was approved by the local ethics committee (Recep Tayyip Erdoğan University Ethics Committee of Non-interventional Research, date: 05.05.2017; number: 2017/74).

RESULTS

Eighty-six clinical *A. baumannii* strains were taken from patients in the ICU of the RTETRH, Turkey, over a 12-month period. The majority of non-duplicate isolates were from tracheal aspirates 29/86 (33.7%), bronchoalveolar lavage 25/86 (29.1%), sputum 19/86 (22.1%), bronchial washing fluid/bronchial brushing 4/86 (4.7%), transbronchial biopsy 4/86 (4.7%), pleural fluid 3/86 (3.4%) and lung aspirates/abscess 2/86 (2.3%).

Analysis of the antibiotic resistance rates of the *A. baumannii* strains revealed that all the strains were resistant to ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, imipenem, and meropenem, and all were sensitive to colistin. Forty-six (53.5%) samples with sensitivity to colistin only were defined as Extensively Drug-Resistant (XDR). The sensitivity rates of the isolates to the antibiotics tested are shown in Table 2.

Table 1: Primers used in the study

Primers	5'-3'	Amplicon Size	Tm	References
<i>bla</i> _{OXA-51-like}	F: TAATGCTTTGATCGGCCTTG R: TGGATTGCACCTTCATCTTGG	353	52°C	10
<i>bla</i> _{OXA-40-like}	F: GGTTAGTTGGCCCCCTTAAA R: AGTTGAGCGAAAAGGGGATT	246	52°C	10
<i>bla</i> _{OXA-23-like}	F: GATCGGATTGGAGAACCAGA R: ATTTCTGACCGCATTTCCAT	501	52°C	10
<i>bla</i> _{OXA-58-like}	F: AAGTAT TGGGGCTTGTGCTG R: CCCCTCTGCGCTCTACATAC	599	52°C	10
<i>bla</i> _{CTX-M1}	F: GCGTGATACCACTTCACCTC R: TGAAGTAAGTGACCAGAATC	260	55°C	11
<i>bla</i> _{CTX-M2}	F: TGATACCACCACGCCGCTC R: TATTGCATCAGAAACCGTGGG	341	55°C	11
<i>bla</i> _{SHV}	F: ATGCGTTATATTCGCCTGTG R: TTAGCGTTGCCAGTGCTC	843	55°C	11
<i>bla</i> _{TEM}	F: AGTATTCAACATTTYCGTGT R: TAATCAGTGAGGCACCTATCTC	847	56°C	11
<i>bla</i> _{NDM}	F: GAGATTGCCGAGCGACTTG R: CGAATGTCTGGCAGCACACTT	497	57°C	10
<i>bla</i> _{VIM}	F: ATTGGTCTATTTGACCGCGTC R: TGCTACTCAACGACTGAGCG	780	58°C	10
<i>bla</i> _{IMP}	F: CATGGTTTGGTGGTTCTTGT R: ATAATTTGGCGGACTTTGGC	488	56°C	10
<i>bla</i> _{GES}	F: ATGCGCTTCATTCACGCAC R: CTATTTGTCCGTGCTCAGGA	863	56°C	10
<i>bla</i> _{KPC}	F: CGTTCCTTGTCTCTCATGGCC R: CCTCGCTGTGCTTGTCTATCC	796	52°C	12
<i>bla</i> _{VEB}	F: ATTTCCCGATGCAAAGCGT R: TTATTCCGGAAGTCCCTGT	542	55°C	10
<i>bla</i> _{PER}	F: ATGAATGTCATCACAAAATG R: TCAATCCGGACTCACT	927	50°C	10
<i>bla</i> _{OXA-48-like}	F: TTGGTGGCATCGATTATCGG R: GAGCACTTCTTTTGTGATGGC	743	57°C	12

Table 2: The antibiogram results of the isolates

Antibiotics	S (n %)	I (n %)	R (n %)
Amikacin (AK)	35 (40.7)	5(5.8)	46 (53.5)
Gentamicin (GN)	23 (26.7)	11 (12.8)	52 (60.5)
Levofloxacin (LEV)	2 (2.3)	4 (4.7)	80 (93.0)
Ciprofloxacin (CIP)	0	2 (2.3)	84 (97.7)
Ceftazidime (CAZ)	0	0	86 (100.0)
Ampicillin-sulbactam (SAM)	0	0	86 (100.0)
Piperacillin/tazobactam (TZP)	0	0	86 (100.0)
Imipenem (IPM)	0	0	86 (100.0)
Meropenem (MEM)	0	0	86 (100.0)
Colistin (COL)	86 (100.0)	0	0
Tigecycline (TIG)	44 (51.2)	34 (39.5)	8 (9.3)
Trimethoprim/sulfamethoxazole (SXT)	11(12.7)	12(14.0)	63(73.3)

Table 3: Distribution of integrase 1 and 2 genes, class 1 and 2 integron gene cassettes and resistant genes

Integrans, genes	n	%
Int I1	39	45.4
Class 1Integron	27	31.4
Int I2	8	9.3
Class 2 Integron	7	8.5
<i>bla</i> _{OXA-51-like}	86	100.0
<i>bla</i> _{OXA-23-like}	82	95.3
<i>bla</i> _{OXA-40-like}	5	5.8
<i>bla</i> _{OXA-58-like}	3	3.5
<i>bla</i> _{TEM}	61	70.9
<i>bla</i> _{SHV}	2	2.3
<i>bla</i> _{CTX-M1}	4	4.7
<i>bla</i> _{CTX-M2}	6	7.0
<i>bla</i> _{OXA-23-like/bla} _{OXA-51-like}	83	96.5
<i>bla</i> _{OXA-23-like/bla} _{OXA-51-like/bla} _{TEM}	59	68.6
<i>bla</i> _{OXA-23-like/bla} _{OXA-51-like/bla} _{CTX-M2}	6	7.0
<i>bla</i> _{OXA-23-like/bla} _{OXA-51-like/bla} _{CTX-M1}	4	4.7
<i>bla</i> _{OXA-58-like/bla} _{OXA-51-like}	3	3.5
<i>bla</i> _{TEM/ bla} _{SHV}	1	1.7
<i>bla</i> _{OXA-40-like/ bla} _{CTX-M1/ bla} _{SHV}	1	1.7
<i>bla</i> _{TEM/bla} _{SHV/ bla} _{CTX-M1/ bla} _{CTX-M2}	1	1.7
<i>bla</i> _{TEM/bla} _{CTX-M2}	1	1.7

Of the 86 strains, integrase I gene positivity was determined in 39 (45.4%), and the class 1 integron gene cassette rate was 27 (31.4%). Integrase II gene positivity was positive in 8 (9.3%) and class 2 gene cassette was determined in 7(8.1%) isolates.

According to the resistance gene analysis, all of 86 (100%) isolates were shown to carry the *bla*_{OXA-51} gene. All strains were negative for *bla*_{OXA-48}, *bla*_{NDM}, *bla*_{VIM}, *bla*_{IMP}, *bla*_{GES}, *bla*_{KPC}, *bla*_{PER} and *bla*_{VEB}. The distribution of the *bla*_{OXA-23}, *bla*_{OXA-40}, *bla*_{OXA-58}, suppressed beta-lactamase resistance genes (*bla*_{TEM-1}, *bla*_{CTX-M2}, *bla*_{CTX-M1} *bla*_{SHV}) and the resistance genes combinations (*bla*_{OXA-23-like/bla}_{OXA-51-like}, *bla*_{OXA-58-like/bla}_{OXA-51-like}, *bla*_{OXA-23-like/bla}_{OXA-51-like/bla}_{CTX-M1}, *bla*_{OXA-23-like/bla}_{OXA-51-like/bla}_{CTX-M2}, *bla*_{OXA-23-like/bla}_{OXA-51-like/bla}_{TEM}, *bla*_{TEM/bla}_{SHV}, *bla*_{OXA-40-like/bla}_{CTX-M1/bla}_{SHV}, *bla*_{TEM/bla}_{SHV/bla}_{CTX-M1/ bla}_{CTX-M2}, and *bla*_{TEM/bla}_{CTX-M2}) are shown in Table 3.

Diagnosis of ventilator-associated pneumonia (VAP) and other healthcare-related pneumonias was based on the criteria set out by the Centers for Disease Control and Prevention. Speed of infection and rates of use of invasive tools were determined as required by the National Hospital Infections Surveillance Web. VAP was defined as a pneumonia involving mechanical ventilation for >2 calendar days at the time of the event, the day of ventilator attachment being taken as day 1, and the ventilator being in place on the date of the event or the previous day.

The number of patients hospitalized at ICU during the study period was 1698, the number of hospital days was 8686, the ventilator use rate was 0.5%, number of

VAPs was 52, the VAP rate was 0.14%, and the VAP infection density was 0.35%. Ventilators use and VAP rates were compatible with that reported rates in our country. Both rates were 50% to 75% according to Ministry of Health 2014 National Hospital Infections Surveillance Web reports.

The most common microorganism species in VAP infections were *A. baumannii* in 58.49%, *Pseudomonas* in 20.75%, and *Acinetobacter* spp. in 1.89% (Table 4). We found that carbapenem resistance rate was more than 90% in our hospital and this rate was compatible the antibiotic resistance report of the microorganism species in the national surveillance reports of the Ministry of Health in our country.

Table 4: The microorganism species in VAP infections

Microorganism Specieses	Number	Rate %
<i>Acinetobacter baumannii</i>	31	58.49
<i>Pseudomonas aeruginosa</i>	11	20.75
<i>Enterobacter aerogenes</i>	2	3.77
<i>Serratia marcescens</i>	2	3.77
<i>Stenotrophomonas maltophilia</i>	2	3.77
<i>Acinetobacter</i> spp.	1	1.89
<i>Escherichia coli</i>	1	1.89
<i>Coagulase-negative staphylococcus</i> (<i>S. epidermidis</i> , <i>S. haemolyticus</i> , <i>S. hyicus</i> , <i>S. lugdunensis</i> , <i>S. saprophyticus</i>)	1	1.89
<i>Pseudomonas</i> spp.	1	1.89

DISCUSSION

MDR *A. baumannii* infections with severe and mortal courses are increasing throughout the world. The treatment and control of *A. baumannii*-related hospital infections is extremely difficult. *A. baumannii* strains have most commonly been isolated from lower respiratory tract samples in previous studies (13-14).

MDR *Acinetobacter* strains create selective suppression of commonly employed antibiotics,

resulting in rapidly spreading and prolonged outbreaks in the hospital environment. In the current study, the most effective antibiotics were identified as colistin (100.0%) and tigecycline (97.3%), while all strains were resistant to ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, imipenem and meropenem. Rates of resistance to ciprofloxacin, levofloxacin, trimethoprim-sulfamethoxazole, gentamicin and amikacin were 97.7%, 93.0%, 73.3%, 60.5% and

53.5%, respectively. The rates of resistance to antibiotics were consistent with those reported in previous studies (13-16).

Among the beta-lactam agents, carbapenems are regarded as the first line agents in the empirical treatment of several serious infections, since they exhibit a very broad-spectrum effect, antimicrobial activity, good clinical efficacy and a positive safety profile. However, in previous studies from Turkey and other countries, as in the current study, resistance to carbapenems in *A. baumannii* isolates has approached close to 100%(13-16). Carbapenem resistance has severely restricted the treatment options in *Acinetobacter* infections, and polymyxins, regarded as the last choice in treatment, have started to be frequently used. The mechanisms related to colistin resistance and the genetic transfer routes of resistance between bacteria have not yet been fully clarified. In some studies, colistin resistance has been determined at a high level of 0-21.3%(13,17-18). No colistin-resistant strains were identified in the present study. The differences in the resistance rates may be related to excessive use of these antibiotics against MDR *A. baumannii*. However, colistin still seems to be the best choice for the treatment of XDR *A. baumannii*.

One long-term study of tigecycline activity in China (19) reported protection of stability with MIC₉₀ ≤4 mg/L, while another study from China reported tigecycline sensitivity at 76.4% in phlegm cultures of patients with MDR-AB and XDR-AB pulmonary infections (20). Previous studies from Turkey have reported resistance rates of 3.8%-27.6%(21-22). In the current study, while tigecycline resistance was determined at 9.3%, the intermediate sensitivity rate was particularly high at 39.5%. Ceftriaxone, cefoperazone-sulbactam, moxifloxacin, and carbapenems are mainly used to treat patients diagnosed with pulmonary infection in our ICU. Other antibiotics are rarely employed.

Since integrons are carried by plasmid or transposons, they are able to pass from one bacterium to another and even from one integron to another within the gene cassette. This strong antibiotic selective suppression causes the spread and transport of antibiotic resistance determinants (14, 23). The presence of class 1 integrons is extremely widespread in *Acinetobacter* species. In the current study, class 1 integron positivity was detected at a rate of 45.4%. High integron transport is important in terms of showing the potential for the spread of MDR *A. baumannii* isolates obtained from clinical samples in our hospital. The presence of integrons in *Acinetobacter* has been implicated in resistance to beta-lactam, aminoglycoside, chloramphenicol, trimethoprim and rifampicin (4). It is known that TMP-SMZ resistance genes (*dhfr*) are located in integrons (9). In this study, susceptibility rates to SXT were determined as 12.7%(11/86) in all isolates and 6.4%(3/47) in isolates containing integron. Class D OXA-type enzymes are recognized as the main contributor to carbapenem resistance in *A. baumannii*. *bla*OXA₅₁ is originally intrinsic to *A. baumannii* and was determined to be 100% positive in our study. It was also used for validation of *A. baumannii* identification. The OXA_{23-like} gene is the best known source of carbapenemase resistance and is transferred via plasmids or chromosomally (6). The *bla*OXA_{23-like} resistance rate in our study was 95.3%. In other studies, *bla*OXA_{23-like} genes have been found in 91.03 - 100.0% of isolates, indicating their responsibility for the dominant carbapenem resistance gene in local *A. baumannii* isolates (3,13,24). OXA_{58-like} producers have generally been reported from Asian and Middle Eastern countries. The highest OXA_{58-like} enzyme production to date was detected in India, at 15%(25). The highest resistance rate reported from Turkey is 53.3%(26). In the current study, OXA_{58-like} was determined at 3.5%. OXA_{58-like} production varies significantly even within countries. ESBLs are mainly transferred by plasmids and are also part of the enzyme family consisting of the

TEM, SHV, and CTX-M groups, and VEB, PER, GES, and KPC. In a study from Saudi Arabia, *A. baumannii* strains were determined with *bla*_{TEM} (71%), and *bla*_{CTX-M} (81%) (27). In another study from Iran in 2015, *bla*_{CTX-M} was not identified, but *bla*_{TEM} (20%), *bla*_{SHV} (58%) and *bla*_{VIM} (30%) were determined (28). In another study from Saudi Arabia, Aly MM et al., determined a lower rate of *bla*_{TEM}, at 14%(15). While a high rate of TEM (70.9%) was observed in the current study, this was followed by CTX-M2 at 6.97%, CTX-M1 at 4.6%, and SHV at 2.3%. Carbapenemase genes from class A, *bla*_{KPC} and *bla*_{GES} types were detected in *A. baumannii*. The prevalence of *bla*_{GES} in the USA and Kuwait has been reported as 95.2%and 0%, respectively (18, 29). *bla*_{KPC} is very rarely seen in *A. baumannii*. In a 12-centre study from Turkey by Beris et al., TEM was identified as the most widespread type in *A. baumannii* isolates at a rate of 55.7%, followed by CTX-M2 at 12.1%, CTX-M1 at 8.1%, SHV at 7.7%and GES at 1.5%. The DNA sequence analysis applied for GES positive isolates identified the GES-11 type (16). In another study from Turkey, by Çiçek et al, GES-11 was determined in 16 of 101 *A. baumannii* isolates and GES-22 in eight. That study was also the first in the literature to demonstrate GES-11 in *A. baumannii* in a Turkish population (10). Zeka et al., reported that GES-11 was detected in five out of 60 isolates in samples from Turkey (30). In addition to GES-11, an *A. baumannii* BM4674 strain was also identified in France by Moubareck et al (31). The *bla*_{PER-1} gene has also been identified in ceftazidime-resistant *A. baumannii* strains across the world (6). While PER positivity was determined in the current study, rates between 18%and 76.3%have been reported in various previous studies (13, 15, 32). *bla*_{VEB}, *bla*_{KPC}, *bla*_{PER} and *bla*_{GES} were not detected in *A. baumannii* isolates. In the current study, no *bla*_{VIM}, *bla*_{IMP} and *bla*_{NDM} positivity was determined, while NDM-1 was reported for the first time in three clinical isolates in Greece in 2016 and in Ethiopia in 2017 (33, 34). NDM-1

positivity in Nepalwas reported at 13.6 %(25). Similarly, to the results of the current study, studies from Kuwait in 2015 and from Iran in 2016 determined *nbla*_{VIM} and *bla*_{IMP} genes any *A. baumannii* isolates (18, 35).

In conclusion, sensitivity to colistin persisted in *A. baumannii* isolates exhibiting high resistance to most antibiotics used in antimicrobial treatment, including carbapenems. A marked increase over time was observed in *bla*_{OXA-23-like} positive isolates in carbapenem-resistant *A. baumannii* clinical isolates. All centers should develop resistance profiles and systematic surveillance networks for the control and observation of resistant isolates. The present study may be regarded as a precursor in terms of revealing the molecular properties, and particularly the presence of integrons in *A. baumannii* isolates produced in lower respiratory tract samples from patients in our hospital. This study can be seen as a pioneer in terms of the molecular properties and especially the presence of integron in *A. baumannii* isolates produced in the lower respiratory tract samples from patients during the years when the causative microorganism was the most common agent. Further studies of these bacteria with epidemiological data will yield a better understanding of the mechanisms causing resistance and the risk factors involved and will thus permit more effective and productive application of infection control and treatment protocols, especially in ICU.

Declaration

Consent for Publication: The authors declare that they have received consent for publication.

Availability of Data and Material: Yes

Competing Interests: The authors declare that they have no competing interests.

Funding: This study was supported by grants from Recep Tayyip Erdogan University-Scientific Research Projects Coordination Unit (Project number: TSA-2017-541)

Authors' Contributions: All the authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria. The manuscript is original, has not already been published, and is not currently under consideration by another journal.

Acknowledgments: Not applicable

Ethics Committe Aproval: Recep Tayyip Erdoğan University Ethics Committe of Non-interventional Research, date: 05.05.2017; number: 2017/74.

REFERENCES

1. Ellis D, Cohen B, Liu J, Larson E. Risk factors for hospital-acquired antimicrobial-resistant infection caused by *Acinetobacter baumannii*. Antimicrobial Resistance and Infection Control. 2015;4(40):1-5. Doi:10.1186/s13756-015-0083-2.
2. Anwar M, Ejaz H, Zafar A, Hamid H. Phenotypic Detection of metallo-beta lactamases in carbapenem resistant *Acinetobacter baumannii* isolated from pediatric patients in Pakistan. J Pathog. 2016;8603964. Doi:10.1155/2016/8603964.
3. Hussein NH, Al-Mathkhury HJF, Sabbah MA. Identification of imipenem-resistant genes in *Acinetobacter baumannii* isolated from Baghdad Hospitals. J Med Microb Diagn. 2014;3(6):170. Doi:10.4172/2161-0703.1000170.
4. Gaur A, Prakash P, Anupurba S, Mohapatra TM. Possible role of integrase gene polymerase chain reaction as an epidemiological marker: study of multidrug resistant *Acinetobacter baumannii* isolated from nosocomial infections. Int J Antimicrob Agents. 2007;29(4):446-50. Doi:10.1016/j.ijantimicag.2006.11.014.
5. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-82. Doi:10.1128/CMR.00058-07.
6. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother. 2010;54(1):24-38. Doi:10.1128/AAC.01512-08.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. M100-S24. USA. Clinical Laboratory Standards Institute, Wayne, 2014.
8. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant *Acinetobacter baumannii*. J Antimicrob Chemother. 2007;59(4):772-774. Doi:10.1093/jac/dkm018.
9. Çopur Çiçek A, Düzgün AO, Saral A, Kayman T, Çizmeci Z, Balci PÖ et al. Detection of class I integron in *Acinetobacter baumannii* isolates collected from nine hospitals in Turkey. Asian Pac J Trop Biomed. 2013;3(9):743-47. Doi:10.1016/S2221-1691(13)60149-5.
10. Çopur Çiçek A, Saral A, Iraz M, Ceylan A, Duzgun AO, Peleg AY et al. OXA- and GES-type β -lactamases predominate in extensively drug-resistant *Acinetobacter baumannii* isolates from a Turkish University Hospital. Clin Microbiol Infect. 2014;20(5):410-5. Doi:10.1111/1469-0691.12338.
11. Copur Cicek A, Saral A, Ozad Duzgun A, Yasar E, Cizmeci Z, Balci PO et al. Nationwide study of *Escherichia coli* producing extended-spectrum β -lactamases TEM, SHV and CTX-M in Turkey. J Antibiot. 2013;66:647-650. Doi:10.1038/ja.2013.72
12. Iraz M, Özad Düzgün A, Sandallı C, Doymaz MZ, Akkoyunlu Y, Saral A et al. Distribution of β -lactamase genes among carbapenem-resistant *Klebsiella pneumoniae* strains isolated from patients in Turkey. Ann Lab Med. 2015;35(6):595-601. Doi:10.3343/alm.2015.35.6.595.
13. Keskin H, Tekeli A, Dolapçı İ, Öcal D. Molecular characterization of beta-lactamase-associated

- resistance in *Acinetobacter baumannii* strains isolated from clinical samples. Mikrobiyol Bul. 2014;48(3):365-376. Doi:10.5578/mb.7796
14. Sarı B, Baran I, Alaçam S, Mumcuoğlu İ, Kurşun Ş, Aksu N. Investigation of oxacillinase genes in nosocomial multidrug-resistant *Acinetobacter baumannii* isolates by multiplex PCR and evaluation of their clonal relationship with rep-PCR. Mikrobiyol Bul. 2015;49(2):249-58. Doi:10.5578/mb.8884.
15. Al-Agamy MH, Khalaf NG, Tawfick MM, Shibl AM, El Kholy A. Molecular characterization of carbapenem-insensitive *Acinetobacter baumannii* in Egypt. Int J Infect Dis. 2014;22:49-54. Doi:10.1016/j.ijid.2013.12.004.
16. Beriş FŞ, Budak EE, Gülek D, Uzun A, Çizmeçi Z, Mengeloğlu FZ et al. Investigation of the frequency and distribution of beta-lactamase genes in the clinical isolates of *Acinetobacter baumannii* collected from different regions of Turkey: a multicenter study. Mikrobiyol Bul. 2016;50(4):511-21. Doi:10.5578/mb.29176
17. Sesli Cetin E, Durmaz R, Tetik T, Otlı B, Kaya S, Çalışkan A. Epidemiologic characterization of nosocomial *Acinetobacter baumannii* infections in a Turkish university hospital by pulsed-field gel electrophoresis. Am J Infect Control. 2009;37(1):56-64. Doi:10.1016/j.ajic.2008.01.010.
18. Leila V, Dashti K, Opazo-Capurro AF, Dashti AA, Obaid KA, Evans BA. Diversity of multi-drug resistant *Acinetobacter baumannii* population in a major hospital in Kuwait. Front Microbiol. 2015;6:743. Doi:10.3389/fmicb.2015.00743.
19. Gao L, Lyu Y, Li Y. Trends in Drug Resistance of *Acinetobacter baumannii* over a 10year period: Nationwide data from the China surveillance of antimicrobial resistance program. Chin Med J(Engl). 2017;130(6):659-64. Doi:10.4103/0366-6999.201601
20. Li P, Wang X, Wang W, Zhao X. Comparison of the efficacies of three empirically selected antibiotics for treating *Acinetobacter baumannii* pulmonary infection: experience from a teaching hospital China. Int J Clin Pharmacol Ther. 2017;55(7):588-93. Doi:10.5414/CP202557.
21. Direkel Ş, Çopur Çiçek A, Karagöz A, Aydoğan Ejder N, Oktay E, Delialioğlu N et al. Antimicrobial susceptibility and molecular characterization of multidrug-resistant *Acinetobacter baumannii* isolated in a university hospital. Mikrobiyol Bul. 2016;50(4):522-34. Doi:10.5578/mb.34158.
22. Çıkman A, Parlak M, Gültepe B, Güdücüoğlu H, Berktaş M. Investigation of tigecycline sensitivity rates in nosocomial *Acinetobacter baumannii* isolates by E-Test. ANKEM Derg. 2011;25(2):79-83. Doi:10.5222/ankem.2011.079.
23. Deng Y, Bao X, Ji L, Chen L, Liu J, Miao J et al. Resistance integrons: class 1, 2 and 3 integrons. Ann Clin Microbiol Antimicrob. 2015;14:45. Doi:10.1186/s12941-015-0100-6.
24. Joshi PR, Acharya M, Kakshapati T, Leungtonkam U, Thummeepak R, Sitthisak S. Co-existence of blaOXA-23 and NDM-1 genes *Acinetobacter baumannii* isolated from Nepal: antimicrobial resistance and clinical significance. Antimicrob Resist Infect Control. 2017;6(21):1-7. Doi:10.1186/s13756-017-0180-5.
25. Khajuria A, Praharaj AK, Kumar M, Grover N. Molecular characterization of carbapenem resistant isolates of *Acinetobacter baumannii* in an intensive care unit of a tertiary care centre at Central India. J Clin Diagn Res. 2014;8(5):38-40. Doi:10.7860/JCDR/2014/7749. 4398.
26. Keyik S, Arslan U, Türk Dağı H, Seyhan T, Fındık D. Investigation of OXA type beta-lactamases and PFGE patterns in *Acinetobacter baumannii* strains

- resistant to carbapenems. Mikrobiyol Bul. 2014;48(4):556-65. Doi:10.5578/mb.8274.
27. Alyamani EJ, Khiyami MA, Booq RY, Alnafjan BM, Altammami MA, Bahwerth FS. Molecular characterization of extended spectrum-beta-lactamases (ESBLs) produced by clinical isolates of *Acinetobacter baumannii* in Saudi Arabia. Ann Clin Microbiol Antimicrob. 2015;14(38):1-9. Doi:10.1186/s12941-015-0098-9.
28. Safari M, Mozaffari Nejad AS, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). Saudi J Biol Sci. 2015;22(4):424-29. Doi:10.1016/j.sjbs.2015.01.004.
29. El-Shazly S, Dashti A, Vali L, Bolaris M, Ibrahim AS. Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of *Acinetobacter baumannii*. Int J Infect Dis. 2015;41:42-9. Doi:10.1016/j.ijid.2015.10.016.
30. Zeka AN, Poirel L, Sipahi OR, Bonnin RA, Arda B, Ozinel MA et al. GES-type and OXA-23 carbapenemase-producing *Acinetobacter baumannii* in Turkey. J Antimicrob Chemother. 2014;69(4):1145-6. Doi:10.1093/jac/dkt465.
31. Moubareck C, Brémont S, Conroy MC, Courvalin P, Lambert T. GES-11, a novel integron-associated GES variant in *Acinetobacter baumannii*. Antimicrob Agents Chemother. 2009;53(8):3579-81. Doi:10.1128/AAC.00072-09.
32. Aşık G, Özdemir M, Kurtoğlu MG, Yağcı S. Detection of the frequency of PER-1 type extended-spectrum β -lactamase-producing *Acinetobacter baumannii* clinical isolates in Turkey: a multicenter study. Turk J Med Sci. 2014;44(6):1041-6. Doi:10.3906/sag-1309-126.
33. Pritsch M, Zeynudin A, Messerer M, Baumer S, Liegl G, Schubert S et al. First report on bla NDM-1 producing *Acinetobacter baumannii* in three clinical isolates from Ethiopia. BMC Infect Dis. 2017;17(1):180. Doi:10.1186/s12879-017-2289-9.
34. Voulgari E, Politi L, Pitiriga V, Dendrinis J, Poulou A, Georgiadis G et al. First report of an NDM-1 metallo- β -lactamase-producing *Acinetobacter baumannii* clinical isolate in Greece. Int J Antimicrob Agents. 2016;48(6):761-62. Doi:10.1016/j.ijantimicag.2016.09.006.
35. Shoja S, Moosavian M, Roztami S, Abbasi F, Tabatabaiefer MA, Peymani A et al. Characterization of oxacillinase and metallo- β -lactames genes and molecular typing of clinical isolates of *Acinetobacter baumannii* in Ahvaz, South-West of Iran. Jundishapur J Microbiol. 2016;9(5):e32388. Doi:10.5812/jjm.32388.